Li Shaoping, a professor from the University of Macau (UM) Institute of Chinese Medical Sciences and deputy director of the State Key Laboratory of Quality Research in Chinese Medicine, has been appointed by Elsevier, the world’s largest medical and scientific publishing house, as an editor of The Journal of Pharmaceutical and Biomedical Analysis (JPBA), effective from 1 January 2018. Prof Li is the first Chinese scholar to have been appointed an editor of JPBA since its establishment in 1983.
JPBA publishes the latest research findings in pharmaceutical and biomedical analysis. It covers analytical technologies in pharmaceutical, biomedical, and clinical sciences, which include methodology, instrumentation, as well as computation and interpretation. It serves as a valuable reference for biochemists, analytical chemists, microbiologists, and specialists in pharmaceutical preparations, as well as pharmaceutical companies, clinical chemistry laboratories, academic institutions, and government departments. It is ranked No 18 (Q1) among 76 SCI journals in analytical chemistry in terms of the impact factor. Its editors are outstanding scholars in the fields of analytical chemistry and pharmaceutical analysis. Prof Li’s appointment as the journal’s editor once again shows international recognition of UM’s research in the quality control of Chinese medicines.
Prof Li has dedicated himself to research studies on the quality control of Chinese medicines since joining UM in 2002. His research projects have received support from the National Natural Science Foundation of China, the Science and Technology Development Fund of the Macao SAR, and the Research Committee of UM. He has contributed to six monographs for the United States Pharmacopoeia for promoting the international standardization of Chinese medicines, and has published more than 300 peer-reviewed papers. A world-renowned scholar in the field of quality control of Chinese medicines and medicinal plants, he is an advisor to the American Herbal Pharmacopoeia, a member of the Chinese Pharmacopoeia Commission, as well as an associate editor of the Journal of Separation Science (Wiley), Chinese Medicine (Springer), and the International Journal of Analytical Chemistry (Hindawi). His study on quality evaluation of dietary supplement from Ganoderma lucidum in US market attracted industrial great attention. He is also the vice chairman of the Chinese Pharmaceutical Association’s pharmaceutical analysis committee, the China Association of Chinese Medicine’s committee for the analysis of Chinese medicines, and the China Association of Traditional Chinese Medicine’s committee for the quality and safety of Chinese medicines.
